Drug crystal form control method based on functionalized colloidal particle stable Pickering emulsion

By using functionalized colloidal particles as heterogeneous nucleation templates in Pickering emulsions, using the liquid-liquid interface, the stability and cost of drug crystal form control are solved, and the fine control and production efficiency of drug crystal form are achieved Improvement.

CN118955379APending Publication Date: 2024-11-15ZHEJIANG UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411008779.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the pharmaceutical industry, it is difficult for the existing technology to effectively control the crystal form of the drug, which affects the quality and efficacy of the drug. The existing methods have problems of stability and high cost in the crystal form control process.

Method used

Functionalized colloidal particles located at the liquid-liquid interface are used as heterogeneous nucleation templates. Through the liquid-liquid interface in the Pickering emulsion, the crystal form of the drug is controlled, and the surface functionalization modification and microfluidic emulsification technology of the colloidal particles are prepared. Stable emulsions are used to induce the formation of specific crystal forms.

Benefits of technology

The fine control of the crystal form of the drug is achieved, and small crystals with uniform particle size are prepared, with good fluidity and compaction, which reduces the cost of equipment investment and shortens production time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955379A_ABST
    Figure CN118955379A_ABST
Patent Text Reader

Abstract

The invention discloses a drug crystal form control method for stabilizing Pickering emulsion based on functionalized colloidal particles, which comprises the following specific operation processes: performing surface functionalization modification on colloidal particles, dispersing the colloidal particles in a continuous phase, taking the colloidal particles as a stabilizer of the Pickering emulsion, dissolving a drug solute in a dispersed phase, mixing the continuous phase, preparing the Pickering emulsion, and preparing the Pickering emulsion. And cooling or evaporative crystallization is carried out in Pickering emulsion liquid drops, such that a crystal product is obtained. According to the invention, on one hand, colloidal particles at a dispersed phase interface are used as a heterogeneous nucleation template to accelerate the nucleation rate and realize crystal form induction, and on the other hand, the colloidal particles have better wrapping property on the dispersed phase to strengthen the spatial constraint on the crystallization process; therefore, crystallization of a specific crystal form under the synergistic effect of a Pickering emulsion space and an interface template effect is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of crystallization, and in particular relates to a drug crystal form control method based on functionalized colloidal particles stabilizing a Pickering emulsion. Background Art

[0002] The control of crystal form is very important, especially in the pharmaceutical industry. Crystal form is an important guarantee for determining drug quality, ensuring efficacy and safety, and achieving commercial production.

[0003] Introducing a heterogeneous nucleation template into a crystallization system and inducing the appearance of a specific crystal form through the specific intermolecular orientation force between the template interface and the solute is an important method for crystal form control. Among them, the introduced template type can be a water-insoluble polymer, such as the public literature reports that functionalized cross-linked terpolymers are used to achieve ROY crystal form control (Crystalline Polymorph Selection and Discovery with Polymer Heteronuclei); it can be a functionalized particle, such as the public literature reports that functionalized nano-silica particles are dispersed in water to achieve glycine crystal form control (Functionalized Silica Nanoparticles as Additives for Polymorphic Control in Emulsion-Based Crystallization of Glycine); it can also be a functionalized surface, such as the public literature reports that functionalized glass substrates are used to achieve carbamazepine crystal form control (Template-induced polymorphic selectivity: the effects of surface chemistry and solute concentration on carbamazepine crystallisation). Summary of the invention

[0004] In view of the prior art, the purpose of the present invention is to provide a method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsions. Different from the prior methods, the present invention utilizes the advantages of large liquid-liquid interface area in Pickering emulsions and the convenience of functionalization modification of colloidal particles used for stabilization, and proposes to use colloidal particles located at the liquid-liquid interface as heterogeneous nucleation templates to achieve the purpose of controlling crystal form.

[0005] The specific technical solutions are as follows: A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion comprises the following steps: 1) Surface functionalization of colloidal particles was performed, and the particles were dispersed in the continuous phase and used as stabilizers for Pickering emulsions; 2) dissolving the drug solute in the dispersed phase and mixing the continuous phase from step 1) to prepare a Pickering emulsion; 3) Cooling or evaporation crystallization in Pickering emulsion droplets to obtain crystalline products. Crystallization occurs in independent emulsion droplets under the action of heterogeneous nucleation induced by interfacial colloidal particles.

[0006] Wherein the solute in step 2) is a small molecule drug, a drug-like molecule or a drug intermediate, other excipients may be further added to the dispersed phase to improve product performance or to coordinately control the target crystal form.

[0007] Furthermore, the colloidal particles in step 1) are inorganic particles, organic particles or proteins with good biocompatibility, preferably silicon dioxide, polysaccharides (starch, cellulose, chitosan) or proteins.

[0008] Furthermore, the functionalization modification in step 1) is a chemical modification method, using one or more reagents such as silanization, alkylation, amination, phosphating, etc., according to the actual crystallization application object, to introduce functional groups that can produce specific intermolecular orientation effects with the solute molecules in step 2), including amino, sulfonic acid, hydroxyl, carboxyl and aromatic groups. During the functionalization, it is necessary to avoid the colloidal particles being too hydrophilic, and the three-phase contact angle is less than 90 degrees to ensure the stability of the formed Pickering emulsion. The hydrophilicity of the colloidal particles can be regulated by regulating the ratio of hydrophilic and hydrophobic functional groups on the surface of the particles. The hydrophilic functional groups include amino, sulfonic acid, hydroxyl, and carboxyl groups, and the hydrophobic functional groups are alkyl and aromatic groups.

[0009] Further, a Pickering emulsion is prepared by microfluid emulsification, wherein the continuous phase is an aqueous phase and the dispersed phase is an organic phase, wherein the organic phase is non-water-soluble or slightly water-soluble and has a high solubility for the target object solute. Preferably, an organic solvent having low viscosity or volatility is additionally provided to facilitate separation of the crystallized product from the solution by filtration or evaporation to obtain a final crystalline product, such as a mixture of one or more of low-carbon chlorinated alkanes, low-carbon ethers, low-carbon alcohols, aromatic hydrocarbons, and low-carbon esters. Compared with other emulsion preparation methods such as homogenization, mechanical stirring, mechanical shaking, and hand shaking, the emulsion prepared by microfluid emulsification has better droplet size uniformity, independence between droplets, and is easy to control the crystallization kinetic conditions.

[0010] Preferably, the organic phase is one or a mixture of two or more of dichloromethane, chloroform, isopropyl ether, amyl alcohol, benzene, toluene and butyl acetate.

[0011] Furthermore, the dispersion concentration of the functionalized colloidal particles in the continuous phase is 0.05-2wt%. The emulsion formed at too low a concentration has poor stability, and too high a concentration has the risk of causing clogging of the microfluidic channel. Generally speaking, the concentration of particles in the Pickering emulsion can vary from low to high, depending on the properties of the particles used and the application requirements. When the concentration of particles is low, the distance between the particles in the emulsion is large, and a higher concentration of surfactant is required to stabilize the emulsion. When the concentration of particles is high, a very stable Pickering emulsion can be formed, and the coverage between the particles is high, which can effectively inhibit the coagulation and phase separation of the emulsion. The stability of the emulsion usually increases proportionally with the increase of the particle concentration. The microfluidic device used is in the micron level. The greater the particle concentration, the greater the risk of clogging, so a suitable concentration range is required.

[0012] Furthermore, the flow rate ratio of the continuous phase and the dispersed phase in the microchannel, that is, the volume ratio is controlled at 2:1-50:1, and the specific range depends on the microfluidic channel structure type and the physical properties of the dispersed phase such as viscosity and surface tension.

[0013] Furthermore, the supersaturation curve of the crystallization process should be strictly controlled during the crystallization process to avoid other uncontrolled heterogeneous nucleation phenomena caused by impurities and bubbles, and at the same time, suitable solvent selection should be used to ensure the dominant role of the heterogeneous nucleation mechanism induced by the interfacial colloidal particles in controlling the crystal form. The specific crystallization process condition parameters are a function of the solute and should be set and optimized according to the crystallization object. In order to ensure that the droplets do not collide and merge with each other during the crystallization process and have good independence, in addition to utilizing the mechanical barrier effect provided by the added colloidal particles at the liquid-liquid interface, stirring of the system should also be avoided during the crystallization process.

[0014] The beneficial effects of the present invention are: On the one hand, the present invention utilizes functionalized colloidal particles located at the liquid-liquid interface of the Pickering emulsion to achieve the induction of a specific crystal form through a heterogeneous nucleation mechanism; on the other hand, the emulsion droplets are used as independent micro-crystallizers to achieve the control of the size of the crystal product through spatial restriction. The prepared crystal product is a spherical agglomerate formed by small crystals, with a uniform particle size distribution smaller than the droplet size, and has good fluidity and compactness. On the basis of crystal form control, the method of the present application integrates crystallization, micronization and granulation into one step, which also greatly reduces the equipment investment cost and effectively shortens the production time. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 is a schematic diagram of the method of the present invention; Figure 2 The particle size and morphology of silica colloidal particles in Example 1; Figure 3 This is an optical microscope image of the microfluidic channel in Example 1; Figure 4 This is an optical microscope image of the spherical crystals of carbamazepine in Example 1; Figure 5 This is the X-ray diffraction (XRD) pattern of carbamazepine in Example 1. DETAILED DESCRIPTION

[0016] The present invention is further described below in conjunction with the accompanying drawings and embodiments, but the protection scope of the present invention is not limited thereto.

[0017] Example 1 1) Preparation of colloidal particles: 348 mL of anhydrous ethanol was placed in a clean glass bottle, and 124 mL of ammonia and 8 mL of deionized water were added to the ethanol, and then 20 mL of ethyl silicate was added. The mixture was rapidly stirred at 25°C for at least 8 h. After the reaction was completed, the mixture was centrifuged at 10,000 rpm for 10 min, and the nanospheres were washed with ethanol for 5 times. After that, the nanospheres were dried at 60°C for 24 h to obtain the following: Figure 2 The particle size shown is silica microspheres with a diameter of about 1 μm.

[0018] 2) Surface amination: The silica microsphere suspension was ultrasonically treated for 15 min to remove lumps and maximize the surface available for functionalization. 450 μL of tri(triethoxysilylpropyl)amine was added to 0.45 g of unfunctionalized silica and suspended in 30 mL of ethanol (95%). The mixture was stirred at room temperature for at least 8 h, centrifuged at 10,000 rpm for 10 min, and the microspheres were washed continuously with ethanol for 5 times. After that, they were dried at 60°C for 24 h to obtain amino-modified silica microspheres. The contact angle test results after modification showed 38 degrees, which was hydrophilic.

[0019] 3) Preparation of ickering emulsion: Figure 1 As shown, functionalized silica is used as a stabilizer for Pickering emulsion, toluene is used as a dispersed phase, and water is used as a continuous phase. An oil-in-water emulsion is prepared by a microfluidic device, wherein the drug carbamazepine is pre-dissolved in the toluene dispersed phase; the amino silica is pre-dispersed in the deionized water continuous phase by ultrasound, wherein the content of silica is 1wt%. Figure 3In the T-shaped channel shown, the continuous phase fluid is transported along the main channel with a height of 250 μm, with a flow rate of 800 μL / min, and the dispersed phase flows in from an orthogonal inlet with a constriction of 50 μm. The flow rate ratio of water to oil is 40:1, and the formed water-in-oil droplets flow from left to right along the main channel, and the droplet size is about 165 μm.

[0020] 4) Cooling crystallization: Cooling crystallization is carried out under static conditions. The droplets prepared above are collected in a reagent bottle and sealed with a lid and a film, and then placed in a jacketed crystallizer at 20°C for cooling crystallization. The temperature is controlled by a water bath and the supersaturation is controlled to 1.6. For each crystallization process, 5 repeated experiments are performed. Spherical crystals with a particle size of approximately 60±5μm are finally obtained by the cooling method ( Figure 4 ). The crystal form of the spherical crystal sample of carbamazepine was characterized by X-ray diffractometer ( Figure 5 ), the more common crystal forms of carbamazepine crystals are needle-shaped type II and tetrahedral type III crystals, among which type II is a metastable crystal form and type III is a stable crystal form. Comparing the standard XRD patterns of type III and type II crystal forms, it can be calculated that the spherical crystal product is a mixture of type II and type III with type II as the main component, showing the induction effect of amino-silica on the metastable type II.

Claims

1. A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion, characterized in that: The steps include: 1) Surface functionalization of colloidal particles was performed, and the particles were dispersed in the continuous phase and used as stabilizers for Pickering emulsions; 2) dissolving the drug solute in the dispersed phase and mixing the continuous phase from step 1) to prepare a Pickering emulsion; 3) Cooling or evaporation crystallization in Pickering emulsion droplets to obtain crystalline products; The solute in step 2) is a small molecule drug, a drug-like molecule or a drug intermediate.

2. A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion according to claim 1, characterized in that: The colloidal particles in step 1) are inorganic particles, organic particles or proteins with good biocompatibility, preferably silicon dioxide, polysaccharide or protein.

3. A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion according to claim 2, characterized in that: The functionalization modification in step 1) is a chemical modification method, which introduces functional groups that can produce specific intermolecular orientation effects with the solute molecules in step 2), including amino groups, sulfonic acid groups, hydroxyl groups, carboxyl groups and aromatic groups.

4. A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion according to claim 3, characterized in that: The Pickering emulsion is prepared by microfluid emulsification, wherein the continuous phase is an aqueous phase, the dispersed phase is an organic phase, and the organic phase is one or a mixture of two or more of low-carbon chlorinated alkanes, low-carbon ethers, low-carbon alcohols, aromatic hydrocarbons, and low-carbon esters.

5. A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion according to claim 4, characterized in that: The organic phase is one or a mixture of two or more of dichloromethane, chloroform, isopropyl ether, amyl alcohol, benzene, toluene and butyl acetate.

6. A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion according to claim 5, characterized in that: The dispersion concentration of the functionalized modified colloidal particles in the continuous phase is 0.05-2wt%.

7. A method for controlling drug crystal form based on functionalized colloidal particles stabilizing Pickering emulsion according to claim 6, characterized in that: The volume ratio of the continuous phase to the dispersed phase is 2:1-50:1.